Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits
© Niimi et al.; licensee BioMed Central Ltd. 2013
Received: 12 September 2013
Accepted: 29 October 2013
Published: 4 November 2013
Probucol and statin are often prescribed for treating atherosclerosis. These two drugs exhibit different mechanisms but it is unknown whether they have the same anti-atherogenic properties. In the current study, we examined whether these two drugs at optimal doses could inhibit the initiation of atherosclerosis in cholesterol-fed rabbits in the same way.
New Zealand White rabbits were fed a cholesterol-rich diet for 5 weeks to produce the early-stage lesions of atherosclerosis. Drug-treated rabbits were administered either probucol or atorvastatin and serum lipids and aortic atherosclerotic lesions were compared with those in a control group.
Atorvastatin treatment significantly reduced serum total cholesterol levels while probucol treatment led to significant reduction of high-density lipoprotein cholesterol levels without changing total cholesterol levels compared with those in the control group. Compared with the control, probucol treatment led to 65% (p < 0.01) reduction while atorvastatin treatment led to 23% (p = 0.426) reduction of the aortic lesion area. Histological and immunohistochemical analyses revealed that the lesions of the probucol-treated group were characterized by remarkable reduction of monocyte adherence to endothelial cells and macrophage accumulation in the intima compared with those of both atorvastatin and control groups. Furthermore, low-density lipoprotein (LDL) isolated from the probucol group exhibited prominent anti-oxidative reaction, which was not present in LDL isolated from either the atorvastatin-treated or the control group.
This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte adherence and infiltration into the subintima. Anti-oxidization of LDL by probucol protects more effectively against early-stage lesion formation than statin-mediated lipid-lowering effects.
Atherosclerosis is a chronic inflammatory disease that is initiated by monocyte adhesion to arterial intimal surfaces followed by migration into the subintimal space. Intimal monocytes are further differentiated into macrophages and then transformed into foam cells after ingesting deposited lipids. High levels of plasma low-density lipoprotein (LDL), especially oxidized LDL, are the major atherogenic factor for the recruitment of monocyte adhesion and induction of foam cell formation [1, 2]. Therefore, reducing plasma LDL levels and inhibition of LDL oxidization are the primary targets for the prevention and treatment of atherosclerotic disease.
Probucol is not only a lipid-lowering drug but also has anti-oxidant activity . For this reason, it is often prescribed for the treatment of hypercholesterolemia and xanthoma. Probucol reduces plasma LDL-cholesterol through increasing LDL catabolism and bile synthesis in the liver [4, 5]. However, in addition to LDL-cholesterol lowering effects, probucol also simultaneously reduces plasma high-density lipoprotein (HDL) levels. In the past, low levels of plasma HDL-cholesterol (HDL-C) induced by probucol were considered as a notorious side effect, but now it is clear that the functions of HDL particles such as reverse cholesterol transport [6–8] and scavenger receptor class B type I activity are actually up-regulated [9, 10]. Previous studies showed that probucol treatment protects against atherosclerosis in WHHL and cholesterol-fed rabbits [11, 12]. Clinically, probucol has been widely used in Asia, such as Japan, China, and Korea, for the treatment of hyperlipidemia and atherosclerosis. Recently, a clinical trial demonstrated that long-term probucol treatment reduced the risk of cardiovascular events in familial hypercholesterolemia . In spite of this, the lipid-lowering effect of probucol is rather moderate compared with that of statins, hydroxymethylglutaryl (HMG)-CoA reductase inhibitors, the most popular lipid-lowering drugs for the treatment of hyperlipidemia. Statins reduce cholesterol biosynthesis through inhibiting HMG-CoA reductase activity and increase hepatic LDL receptor activity . Furthermore, statins also have anti-inflammatory effects designated as pleiotropic effects. Nevertheless, treatment with statin therapy alone can lead to only 30% reduction of the incidence of coronary events [15, 16]. Therefore, other non-statin therapies are required for many patients who are not responsive to statins [2, 17].
In the current study, we compared these two drugs in terms of atheroprotective effects in cholesterol-fed rabbits. We were particularly interested in the initiation of atherosclerosis and made a side-to-side comparison of these two drugs. Our results suggested that the anti-oxidative effects exerted by probucol may be more beneficial for the inhibition of monocyte adhesion and infiltration during atherogenesis than statin-mediated cholesterol lowering effects.
Serum lipids and lipoprotein profile
Scanning electron microscopic observation
In the current study, we compared the atheroprotective effects of probucol and atorvastatin, two hypolipidemic drugs for the treatment of hyperlipidemia. It is generally believed that probucol reduces plasma cholesterol through increasing LDL catabolism and bile excretion, whereas atorvastatin inhibits HMG-CoA reductase activity and increases hepatic LDL receptor activity . Here, we demonstrated that, at the optimal doses of each drug, probucol exerts a greater inhibitory effect on the initiation of cholesterol-diet-induced atherosclerosis in rabbits than atorvastatin. It has been reported previously that probucol at high dose (1%) and for a long period (2 ~ 6 months) protects against atherosclerosis in both WHHL and cholesterol-fed rabbits [11, 12]. Here, we further demonstrated that probucol even at lower dose (0.3%) for a short period (4 weeks) was still able to reduce the lesions of atherosclerosis in cholesterol-fed rabbits and the lesions were characterized by reduced intimal macrophage accumulation. It is interesting to note that, unlike atorvastatin, probucol administration for a short period did not lead to a significant cholesterol-lowering effect, while HDL-C was significantly low. Therefore, several possible mechanisms may operate independently upon the lipid-lowering effect regarding probucol’s anti-atherogenic effects. First, probucol has very strong anti-oxidative effects, whereas atorvastatin does not. In this situation, one may consider that the anti-atherogenic effects induced by anti-oxidation by probucol are stronger than the lipid-lowering effects of atorvastatin. It may also suggest that oxidation in the arterial wall may be more important than merely elevation of plasma cholesterol in the initiation of atherosclerosis. The second possible mechanism may be attributed to HDL modulation induced by probucol. It has been reported that HDL functions such as reverse cholesterol transport [6–8] and anti-oxidative activity  are markedly up-regulated in probucol-treated patients, while HDL-C levels are low. If these functions occur in the arterial wall, accumulation of lipids would be diminished. Nevertheless, these results may raise an important question: Do we need to treat hyperlipidemic patients with atorvastatin combined with probucol? In Japan, probucol is used for hyperlipidemic patients who are resistant to statins [19, 20]. In China, however, probucol is widely used for the treatment of hyperlipidemia and given the same priority as statins. So-called “PAS” therapy (probucol, aspirin, and statin) in China is often prescribed for hyperlipidemic patients for both primary and secondary prevention of coronary artery diseases . Although this question still awaits more clinical investigation, apparently, the anti-oxidative capacity is superior to the lipid-lowering effect for protection against atherosclerosis initiation.
Our studies provide evidence that probucol inhibited the initiation of atherosclerosis without improving serum TC levels, despite a lowering of serum HDL-C levels. These results suggest that the anti-oxidative effects exerted by probucol are more efficient and effective for the inhibition of atherosclerosis than the cholesterol-lowering effects.
Probucol was synthesized at Otsuka Pharmaceutical Co., Ltd. (Tokushima, Japan). Atorvastatin calcium was purchased from Sequoia Research Products Ltd. (Pangbourne, UK).
Male New Zealand White rabbits (1.0-1.5 kg at age of 6-7 weeks old) provided by Kitayama Labes Co., Ltd. (Nagano, Japan) were fed an atherogenic diet containing 0.5% cholesterol for 1 week. Using the TC levels (around 700 mg/dl), we selected those rabbits that showed a reasonable response to cholesterol diet feeding for the following experiments. These rabbits were further fed with either the same atherogenic diet (vehicle group) or supplemented with either 0.3% (w/w) probucol or 0.005% (w/w) atorvastatin for another 4 weeks. All diets were prepared by Oriental Yeast Co., Ltd. (Tokyo, Japan). Blood samples were obtained from the auricular vein biweekly for biochemical analysis. At the end of the experiment, all rabbits were sacrificed for evaluation of aortic atherosclerosis. All animal experiments were performed with the approval of the Animal Care Committee of Otsuka Pharmaceutical Company and the University of Yamanashi.
Analysis of serum biochemistry
Serum levels of TC, TG, and HDL-C were measured using commercial assay kits (Wako Pure Chemical Industries Ltd., Osaka, Japan) and automated clinical analyzer BIOLIS 24i (Tokyo Boeki Machinery, Ltd., Tokyo, Japan).
Analysis of lipoproteins using HPLC
Serum lipoproteins were analyzed using HPLC (Tosoh Co., Tokyo, Japan) according to the procedure described by Usui et al. with slight modification. In brief, sera were separated on 2 tandem connected gel filtration columns TSKgel LipopropakXL (Tosoh Co., Tokyo, Japan) with phosphate-buffered saline containing 0.005% Brij-35 and 0.05% sodium azide. The column effluent was mixed with on-line connected cholesterol colorimetric reagent (Wako Pure Chemical Industries Ltd., Osaka, Japan) and the absorbance at 600 nm was monitored after the enzymatic reaction in a reaction coil at 37°C. The lipoprotein fractions of very-low-density lipoprotein, LDL, and HDL were defined based on retention time.
Analysis of aortic atherosclerosis
At the end of the experiment, all rabbits were euthanized by injection of an overdose of sodium pentobarbital solution. Aortas were rapidly dissected free from the arch to the iliac artery bifurcation. The aortas were analyzed for en face gross lesions and microscopic quantification of intimal lesion areas. En face lesion area was quantitated as described previously . Aortas were opened longitudinally and mounted on a black rubber board, and then were photographed using a digital camera. Using Photoshop software (Adobe Systems Inc., San Jose, CA), atherosclerotic lesions were visualized first and then quantitatively measured using the image analysis system WinRoof (Mitani Co., Tokyo, Japan). For microscopic lesion analysis, two segments (aortic arch and thoracic aorta) fixed in 10% formalin were embedded in OCT compound (Sakura Finetek Japan Co., Ltd., Tokyo, Japan). Frozen sections were stained with hematoxylin-eosin (HE) and elastica van Gieson (EVG). The intimal lesion size was quantitatively measured using the image analysis system WinRoof as described previously . For microscopic evaluation of the cellular components of the lesions, serial frozen sections of the aorta were immunohistochemically stained with RAM11 (Dako Japan Inc., Tokyo, Japan) monoclonal antibody against rabbit macrophage using Histofine Simple Stain MAX-PO(M) kits (Nichirei Biosciences Inc., Tokyo, Japan). Macrophages in the lesions were measured by quantifying the positively stained area using the image analysis system.
Scanning electron microscopic observation
To observe intimal surface changes of aorta after cholesterol-rich diet feeding, we perfused three rabbits from each group at the end of the experiment using phosphate-buffered saline followed by fixative solution containing 2.5% glutaraldehyde and 2% paraformaldehyde (pH 7.4) for 20 min. After that, aortas were dissected free from the aortic root to the common carotid artery bifurcation. Aorta was cut into 13 pieces as specimens (approximately 3 mm square). These specimens were further fixed in the same solution at 4°C overnight. Fixed specimens were post-fixed with 1% osmium tetroxide (pH 7.4) and dehydrated with graded ethanol followed by isoamyl acetate. Aortic segments were dried in CO2 using critical point dryer HCP-2 (Hitachi Koki Co. Ltd., Tokyo, Japan) and were sputter-coated with a thin gold layer in an ion coater IB-3 (EIKO Co., Tokyo, Japan). The aortic surface was examined under a scanning electron microscope JSM-6510 (JEOL Ltd., Tokyo, Japan).
Evaluation of LDL oxidizability
Plasma LDLs (d = 1.006-1.063) were isolated by ultracentrifugation  from rabbits at 4 weeks after cholesterol-rich-diet feeding. The susceptibility of LDL to copper-induced oxidation was assessed by determining the formation of conjugated dienes as described previously . In brief, LDL (50 μg protein/mL) was incubated with 5 μM CuSO4, and the formation of conjugated dienes was determined by monitoring the change of absorbance at 234 nm at 37°C with a microplate reader SpectraMax 190 (Molecular Devices, Sunnyvale, CA). Lag-time, maximal oxidization speed, and maximal diene concentrations were calculated for the estimation of oxidization sensitivity.
All data were expressed as mean ± SEM. Statistical significance was determined by one-way ANOVA (Dunnett’s test) using SAS software (SAS Institute Japan Ltd., Tokyo, Japan). P values less than 0.05 were considered significant or otherwise specified.
- Moore KJ, Tabas I: Macrophages in the pathogenesis of atherosclerosis. Cell. 2011, 145: 341-355. 10.1016/j.cell.2011.04.005PubMed CentralView ArticlePubMedGoogle Scholar
- Libby P, Ridker PM, Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature. 2011, 473: 317-325. 10.1038/nature10146View ArticlePubMedGoogle Scholar
- Yamashita S, Matsuzawa Y: Where are we with probucol: a new life for an old drug?. Atherosclerosis. 2009, 207: 16-23. 10.1016/j.atherosclerosis.2009.04.002View ArticlePubMedGoogle Scholar
- Naruszewicz M, Carew TE, Pittman RC, Witztum JL, Steinberg D: A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J Lipid Res. 1984, 25: 1206-1213.PubMedGoogle Scholar
- Nestel PJ, Billington T: Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis. 1981, 38: 203-209. 10.1016/0021-9150(81)90117-9View ArticlePubMedGoogle Scholar
- Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T, Takami S, Koyama M, Kameda-Takemura K, Matsuzawa Y: High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 1997, 27: 285-292. 10.1046/j.1365-2362.1997.1040657.xView ArticlePubMedGoogle Scholar
- Adlouni A, El Messal M, Saïle R, Parra H, Fruchart J, Ghalim N: Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles. Atherosclerosis. 2000, 152: 433-440. 10.1016/S0021-9150(99)00493-1View ArticlePubMedGoogle Scholar
- Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, Rader DJ: Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Circulation. 2011, 124: 1382-1390. 10.1161/CIRCULATIONAHA.110.009704PubMed CentralView ArticlePubMedGoogle Scholar
- Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR: Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999, 19: 1325-1332. 10.1161/01.ATV.19.5.1325View ArticlePubMedGoogle Scholar
- Hirano K, Ikegami C, Tsujii K, Zhang Z, Matsuura F, Nakagawa-Toyama Y, Koseki M, Masuda D, Maruyama T, Shimomura I, Ueda Y, Yamashita S: Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol. 2005, 25: 2422-2427. 10.1161/01.ATV.0000185834.98941.3dView ArticlePubMedGoogle Scholar
- Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA. 1987, 84: 5928-5931. 10.1073/pnas.84.16.5928PubMed CentralView ArticlePubMedGoogle Scholar
- Daugherty A, Zweifel BS, Schonfeld G: Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol. 1989, 98: 612-618. 10.1111/j.1476-5381.1989.tb12635.xPubMed CentralView ArticlePubMedGoogle Scholar
- Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2008, 15: 292-303. 10.5551/jat.E610View ArticlePubMedGoogle Scholar
- Tobert JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003, 2: 517-526. 10.1038/nrd1112View ArticlePubMedGoogle Scholar
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005, 366: 1267-1278.View ArticlePubMedGoogle Scholar
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, : Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010, 376: 1670-1681. 10.1016/S0140-6736(10)61350-5View ArticlePubMedGoogle Scholar
- Brautbar A, Ballantyne CM: Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol. 2011, 8: 253-265. 10.1038/nrcardio.2011.2View ArticlePubMedGoogle Scholar
- Inagaki M, Nakagawa-Toyama Y, Nishida M, Nakatani K, Nakaoka H, Kawase M, Kawase R, Tsubakio-Yamamoto K, Masuda D, Ohama T, Matsuyama A, Ishigami M, Komuro I, Yamashita S: Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2012, 19: 643-656. 10.5551/jat.12807View ArticlePubMedGoogle Scholar
- Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S: Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012, 19: 1043-1060. 10.5551/jat.14621View ArticlePubMedGoogle Scholar
- Japan Atherosclerosis Society: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. 2012, TokyoGoogle Scholar
- Adhikari BK, Meng X: Challenges of PAS therapy for coronary atherosclerotic plaque reversal [abstract]. Heart. 2012, 98: E167-View ArticleGoogle Scholar
- Usui S, Hara Y, Hosaki S, Okazaki M: A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002, 43: 805-814.PubMedGoogle Scholar
- Ito H, Uehara K, Matsumoto Y, Hashimoto A, Nagano C, Niimi M, Miyakoda G, Nagano K: Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits. PLoS One. 2012, 7: e39374- 10.1371/journal.pone.0039374PubMed CentralView ArticlePubMedGoogle Scholar
- Waqar AB, Koike T, Yu Y, Inoue T, Aoki T, Liu E, Fan J: High-fat diet without excess calories induces metabolic disorders and enhances atherosclerosis in rabbits. Atherosclerosis. 2010, 213: 148-155. 10.1016/j.atherosclerosis.2010.07.051View ArticlePubMedGoogle Scholar
- Hatch FT: Practical method for plasma lipoprotein analysis. Adv Lipid Res. 1968, 6: 1-68.PubMedGoogle Scholar
- Wang Y, Niimi M, Nishijima K, Waqar AB, Yu Y, Koike T, Kitajima S, Liu E, Inoue T, Kohashi M, Keyamura Y, Yoshikawa T, Zhang J, Ma L, Zha X, Watanabe T, Asada Y, Chen YE, Fan J: Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2013, 33: 224-231. 10.1161/ATVBAHA.112.300445PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.